Leukemia, B-Cell  >>  Gazyva (obinutuzumab)  >>  Phase 3
Welcome,         Profile    Billing    Logout  

4 Trials

Remove FilterRemove FilterRemove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Gazyva (obinutuzumab) / Roche, Biogen
NCT01010061: CLL11: A Study of Obinutuzumab (RO5072759 [GA101]) With Chlorambucil in Patients With Previously Untreated Chronic Lymphocytic Leukemia (Stage 1a)

Checkmark EHA 2016
May 2016 - May 2016: EHA 2016
Checkmark EHA 2016
May 2016 - May 2016: EHA 2016
Checkmark ISH 2016
More
Completed
3
787
Canada, US, Europe, RoW
obinutuzumab, RO5072759, GA101, GAZYVA®, rituximab, Rituxan®, MabThera®, chlorambucil
Hoffmann-La Roche, German CLL Study Group, Genentech, Inc.
Lymphocytic Leukemia, Chronic
07/12
08/17
NCT01998880: CLL11: A Study of Rituximab With Chlorambucil or Chlorambucil Alone in Patients With Previously Untreated Chronic Lymphocytic Leukemia (Stage 1b)

Completed
3
787
Canada, US, Europe, RoW
obinutuzumab, RO5072759, GA101, GAZYVA®, rituximab, Rituxan®, MabThera®, chlorambucil
Hoffmann-La Roche, German CLL Study Group, Genentech, Inc.
Lymphocytic Leukemia, Chronic
08/12
08/17
NCT02053610: CLL11: A Study of Obinutuzumab (RO5072759 [GA101]) With Chlorambucil in Patients With Previously Untreated Chronic Lymphocytic Leukemia (Stage 2)

Completed
3
787
Canada, US, Europe, RoW
obinutuzumab, RO5072759, GA101, GAZYVA®, Gazyvaro, rituximab, Rituxan®, MabThera®, chlorambucil
Hoffmann-La Roche, German CLL Study Group, Genentech, Inc.
Lymphocytic Leukemia, Chronic
08/13
08/17
NCT01980875 / 2013-004551-20: Efficacy and Safety of Idelalisib in Combination With Obinutuzumab Compared to Chlorambucil in Combination With Obinutuzumab for Previously Untreated Chronic Lymphocytic Leukemia

Terminated
3
57
Canada, US, Europe, RoW
Idelalisib, GS-1101, CAL-101, Zydelig®, Chlorambucil, Obinutuzumab
Gilead Sciences
Chronic Lymphocytic Leukemia
05/16
05/16

Download Options